Company profile
Pressure BioSciences, Inc.
OTC: PBIO · Healthcare · Medical - Specialties
PublicHQ Canton, MACIK 0000830656Reports USD
#803 of 1,422 Healthcare companies by revenue61st-percentile growth
EA Score
——FH —DQ 48GM —SS 47
v0.1 · 25/100 weight · pillars only
↑ listing tenure, disclosure history · ↓ return on assets, balance-sheet leverage
Methodology →Revenue TTM
$1.5M
Rev growth YoY (TTM)
-25.3%
Net income (FY)
-$29.3M
Employees
16
as of 2026-08-29
Market cap
$16.4k
as of 2026-08-29
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$2.0M$2.0M2023
Net income-$29.3M-$29.3M2023
Operating income-$9.5M-$9.5M2023
Total assets$1.0M$1.0M2023
Liabilities$33.8M$33.8M2023
Equity-$32.8M-$32.8M2023
Revenue trend
FY2016 – FY2023 · USD
FY16
FY18
FY18
FY19
FY20
FY21
FY22
FY23
Revenue by segment
Filed disclosures · FY2023
By product
Hardware56%
Transferred Over At Time12%
Consumables10%
Agrochem Products9%
Sample Preparation Accessories6%
Contract Research Services4%
By geography
North America69%
Asia24%
Europe7%
The read
What is Pressure BioSciences, Inc.’s revenue?
Pressure BioSciences, Inc. booked $2.0M in FY2023 revenue, growing 14% year over year — faster than most Healthcare companies we track, at a -1482.2% net margin.
Peers · Healthcare
Sagimet Biosciences Inc.36DOramed Pharmaceuticals Inc.61CRapid Dose Therapeutics Corp.38DLipocine Inc.48DTHC Biomed Intl Ltd.——iSpecimen Inc.29DKey facts
CEORichard T. Schumacher
SectorHealthcare
IndustryMedical - Specialties
HeadquartersCanton, MA
ExchangeOTC: PBIO
Employees16
IPO date1996-10-31
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.